Literature DB >> 15767487

Tadalafil associated with anterior ischemic optic neuropathy.

George K Escaravage1, John D Wright, Syndee J Givre.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15767487     DOI： 10.1001/archopht.123.3.399

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN： 0003-9950


× No keyword cloud information.
  9 in total

1.  Can erectile dysfunction drug use lead to ischaemic optic neuropathy?

Authors:  H D Pomeranz
Journal:  Br J Ophthalmol       Date:  2006-02       Impact factor: 4.638

2.  Non-arteritic anterior ischaemic optic neuropathy and the treatment of erectile dysfunction.

Authors:  G McGwin; M S Vaphiades; T A Hall; C Owsley
Journal:  Br J Ophthalmol       Date:  2006-02       Impact factor: 4.638

Review 3.  Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date.

Authors:  Alan M Laties
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 4.  Erectile dysfunction drugs and risk of anterior ischaemic optic neuropathy: casual or causal association?

Authors:  Helen V Danesh-Meyer; Leonard A Levin
Journal:  Br J Ophthalmol       Date:  2007-11       Impact factor: 4.638

Review 5.  Phosphodiesterase type 5 inhibitors, visual changes, and nonarteritic anterior ischemic optic neuropathy: is there a link?

Authors:  Konstantinos Hatzimouratidis
Journal:  Curr Urol Rep       Date:  2007-11       Impact factor: 3.092

6.  Bilateral sequential non-arteritic anterior ischaemic optic neuropathy following repeat influenza vaccination.

Authors:  Gemma Manasseh; Debbie Donovan; Emily H Shao; Simon R Taylor
Journal:  Case Rep Ophthalmol       Date:  2014-08-23

7.  Anterior Ischemic Optic Neuropathy in a Patient with Erectile Dysfunction: Tadalafil as an Offending Medication.

Authors:  Alireza Dehghani; Mohammad-Hasan Alemzadeh-Ansari; Marjan Masjedi; Arman Amirkhani; Mohsen Pourazizi
Journal:  J Res Pharm Pract       Date:  2018 Jul-Sep

Review 8.  Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction.

Authors:  R Sadovsky; G B Brock; S W Gutkin; S Sorsaburu
Journal:  Int J Clin Pract       Date:  2009-08       Impact factor: 2.503

9.  Chronic low dosing of phosphodiesterase type 5 inhibitor for erectile dysfunction.

Authors:  Hyun Hwan Sung; Sung Won Lee
Journal:  Korean J Urol       Date:  2012-06-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.